The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Exclusive: Genentech plans to cut 3% of workforce across several units, company says
Roche’s Genentech unit will cut 3% of workers, a spokesperson told Endpoints News Wednesday, making it the latest drugmaker to announce staffing reductions in recent